Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Scott Kopetz, MD, PhD, reported a financial interest/relationship or affiliation in the form of Stocks and other ownership interests: MolecularMatch, Navire, Lutris, and Iylon. Consultant: Genentech, Inc; EMD Serono, Inc; Merck & Co, Inc; Holy Stone; Novartis Pharmaceuticals Corp; Lilly USA; Boehringer Ingelheim; Boston Biomedical; AstraZeneca Pharmaceuticals/MedImmune; Bayer HeatlhCare, Inc; Pierre Fabre; EMD Serono, Inc; Redx Pharma; Ipsen Pharmaceuticals; Daiichi-Sankyo, Inc; Natera, Inc; HalioDx, Lutris; Jacobio; Pfizer, Inc; Repare Therapeutics; Inivata; GlaxoSmithKline; Jazz Pharmaceuticals; Iylon; Xilis; AbbVie; Amal Therapeutics; Gilead Sciences; Mirati Therapeutics; Flame Biosciences; Servier; Carina Biotechnology; Bicara Therapeutics; Endeavor BioMedicines; and Numab Pharma. Research funding to MD Anderson Cancer Center: sanofi; Biocartis; Guardant Health, Inc; Array BioPharma; Genentech/Roche; EMD Serono, Inc; MedImmune; Novartis Pharmaceuticals Corp; Amgen, Inc; Lilly USA; and Daiichi-Sankyo, Inc.
Rona Yaeger, MD, reported a financial interest/relationship or affiliation in the form of Advisor: Array BioPharma/Pfizer, Natera, and Mirati Therapeutics. Research grant: Pfizer, Inc and Boehringer Ingelheim.
The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Jeffrey Stein; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Facebook Comments